Welcome to our dedicated page for Eyenovia news (Ticker: EYEN), a resource for investors and traders seeking the latest updates and insights on Eyenovia stock.
Eyenovia Inc (EYEN) is a clinical-stage biopharmaceutical innovator advancing precision ophthalmic therapies through its proprietary microdosing technology. This page serves as the definitive source for verified company news, including clinical trial milestones, regulatory updates, and strategic partnerships shaping the future of eye care.
Investors and industry professionals will find timely updates on key initiatives such as Optejet delivery system advancements, pipeline developments for mydriasis and myopia treatments, and commercialization progress. Our curated news collection ensures transparent access to material events impacting Eyenovia's position in the ophthalmic therapeutics market.
Content highlights include FDA submission announcements, partnership agreements with healthcare providers, research publications, and financial performance updates. All information is sourced directly from official company communications to maintain accuracy and compliance.
Bookmark this page for streamlined access to Eyenovia's latest developments in microdose array print (MAP) technology and its application in improving ocular treatment outcomes. Regularly updated to reflect the evolving landscape of precision ophthalmology.
Eyenovia (NASDAQ: EYEN) has entered a collaboration agreement with Senju Pharmaceutical to develop Senju's SJP-0035 for use with Eyenovia's Optejet® dispensing technology as a potential treatment for chronic dry eye disease. The companies plan to meet with the FDA to present a clinical development proposal for a novel drug-device combination product. Dry eye affects nearly 16 million Americans, with treatment costs totaling over $3 billion in the U.S. and $5 billion globally.
SJP-0035 has shown favorable tolerability in prior Phase 1 and 2 studies. The collaboration aims to create a more efficacious and differentiated treatment by integrating SJP-0035 with the Optejet platform. The companies anticipate meeting with the FDA later this year, followed by a Phase 2b study in 2025 and potentially two Phase 3 studies by 2026.
NovaBay Pharmaceuticals and Eyenovia have started joint promotional activities to market NovaBay's Avenova® Antimicrobial Lid & Lash Solution and Eyenovia's MydCombi™ for mydriasis to large ophthalmic surgery centers. Eyenovia's salesforce will promote Avenova, while NovaBay prepares for Eyenovia's upcoming launch of Clobetasol Propionate Ophthalmic Suspension, 0.05% in August 2024. This partnership aims to enhance market presence and awareness for both companies' products, leveraging NovaBay's established network of eyecare professionals. Prescription Avenova is available through EyenoviaRx.com and Avenova.com, with the non-prescription version on Amazon.com.
Eyenovia announced the pricing of a $5 million registered direct offering, involving the sale of 7,575,757 shares of common stock and accompanying warrants. Each share and warrant combination is priced at $0.66, with warrants exercisable at $0.69 per share starting six months from issuance and expiring in 5.5 years. The offering is expected to close around July 1, 2024, subject to customary conditions. Gross proceeds are anticipated to be $5 million before fees and expenses. The funds will support the commercialization of Mydcombi and clobetasol propionate, the CHAPERONE pediatric myopia study, and general corporate purposes, including debt repayment. Chardan is leading the placement, with Brookline Capital Markets acting as co-placement agent.
Eyenovia (NASDAQ: EYEN) reported its Q1 2024 financial results and updates on key products. The company aims to accelerate the development of MicroPine, a late-stage product for pediatric progressive myopia, and anticipates a 3Q 2024 launch for clobetasol propionate ophthalmic suspension, a new steroid for post-ocular surgery inflammation and pain. Additionally, Eyenovia has trained and shipped products to 50 new Mydcombi-using offices since April 2024.
Financially, the company reported a net loss of $10.9 million or $0.23 per share, compared to a $5.7 million loss or $0.15 per share in Q1 2023. Operating expenses increased by 88.1% year-over-year, partly due to reacquiring MicroPine license rights. Eyenovia reduced anticipated cash-based expenses by $0.8 million per quarter and had $8.0 million in cash and equivalents as of March 31, 2024.
The company has completed manufacturing capabilities with FDA approval for three facilities. A conference call and webcast are scheduled for May 15, 2024, at 4:30 pm ET.
Eyenovia (NASDAQ: EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, will report its Q1 2024 financial results on May 15, 2024, after the market closes.
A conference call and webcast will follow at 4:30 p.m. ET to review the financial and operating results. Participants can join the call at 1-800-717-1738 (domestic) or 1-646-307-1865 (international). Live and archived webcasts will be available on the investor relations page of Eyenovia's website.
FAQ
What is the current stock price of Eyenovia (EYEN)?
What is the market cap of Eyenovia (EYEN)?
